Literature DB >> 22858126

Scleral patch grafts in the management of uveal and ocular surface tumors.

Manabjyoti Barman1, Paul T Finger, Tatyana Milman.   

Abstract

OBJECTIVE: To evaluate the outcome of scleral patch grafts in a series of patients undergoing management for uveal and ocular surface tumors.
DESIGN: Case series. PARTICIPANTS: Ten patients underwent scleral patch grafting. Five patients had uveal melanoma with extrascleral extension, 2 patients had scleromalacia secondary to plaque radiotherapy for uveal melanoma, 2 patients had suspicious uveoscleral nevi, and 1 patient had invasive conjunctival squamous cell carcinoma with scleral necrosis.
METHODS: Retrospective, interventional, noncomparative chart review of patients undergoing treatment for ocular tumors followed by scleral grafts in a tertiary eye care center in the United States between September 2003 and January 2011. Sclera was reconstructed with allogenic scleral grafts. Clinical observations were performed after grafting. MAIN OUTCOME MEASURES: Structural integrity, appearance, and stability of the grafts.
RESULTS: Ten patients were reviewed. All melanoma cases received plaque radiotherapy with palladium 103. The cases with nevi and squamous cell carcinoma underwent local resection with cryotherapy as primary treatment. In 8 cases, scleral grafting was performed as part of the initial surgery. In all of these cases, satisfactory anatomic and functional outcomes were achieved. In 2 cases with scleromalacia secondary to radiotherapy for uveal melanoma, grafts were placed several years after the initial treatment. In these 2 cases, one showed signs of graft retraction, whereas another showed graft thinning. No patients experienced graft infection, rejection, or tumor recurrence.
CONCLUSIONS: In this series, scleral grafts were well accepted when placed as part of the primary tumor management despite synchronous radiotherapy, scleral resection, or cryotherapy. Grafting was less successful when performed as a late procedure for radiation-induced scleromalacia. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22858126     DOI: 10.1016/j.ophtha.2012.06.024

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  3 in total

1.  Scleral Thinning after Transscleral Biopsy for Uveal Melanoma Using Lamellar Scleral Flap.

Authors:  Diane T Siegel; Eszter Szalai; Jill R Wells; Hans E Grossniklaus
Journal:  Ocul Oncol Pathol       Date:  2018-02-23

Review 2.  Case series of scleral patch grafts during COVID-19 pandemic.

Authors:  E Lalitha Siva Jyothi; O Gopala Krishna; P Lakshmana Rao; P Raja Sekhar
Journal:  Indian J Ophthalmol       Date:  2021-09       Impact factor: 1.848

3.  RD repair using 360-degree scleral graft for extensive scleral ectasia in a patient with Ehlers Danlos syndrome.

Authors:  Shane Whitlow; Zubair Idrees
Journal:  Am J Ophthalmol Case Rep       Date:  2019-09-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.